Lupin

Lupin Receives Approval from U.S. FDA for Rivaroxaban for Oral Suspension.

30 Sep, 2025 | 04:55pm • Source: BSE

Retirement of Senior Management Personnel

30 Sep, 2025 | 04:04pm • Source: BSE

Lupin Limited has informed the Exchange that Nanomi B.V., the Netherlands, a wholly owned subsidiary of the Company in Netherlands, has entered into a definitive...

29 Sep, 2025 | 09:56am • Source: NSE

Intimation of Closure of Trading Window.

26 Sep, 2025 | 04:32pm • Source: BSE

Details of voting results of the business transacted by way of Postal Ballot along with report of the Scrutinizer.

25 Sep, 2025 | 08:58pm • Source: BSE

Lupin Receives Tentative Approval from U.S. FDA for Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets.

24 Sep, 2025 | 04:44pm • Source: BSE

Intimation regarding allotment of 3351 shares under ESOP.

23 Sep, 2025 | 11:13am • Source: BSE

U.S. FDA has conducted a product-specific Pre-Approval Inspection at the Company''s Pune Biotech facility.

20 Sep, 2025 | 01:49pm • Source: BSE

Lupin Receives Approval from U.S. FDA for Lenalidomide Capsules.

17 Sep, 2025 | 01:08pm • Source: BSE

U.S. FDA has conducted an inspection of Company''s Injectable facility at Nagpur.

16 Sep, 2025 | 09:24pm • Source: BSE

Intimation about participating in the Analyst/Investors Meet.

11 Sep, 2025 | 12:08pm • Source: BSE

Newspaper Publication for the information regarding Special Window for re-lodgement for transfer request of physical shares.

03 Sep, 2025 | 04:05pm • Source: BSE

Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi''s Long-Acting Injectable Platform.

03 Sep, 2025 | 01:04pm • Source: BSE

Lupin Limited has informed the Exchange about ESG Rating by Crisil ESG Ratings & Analytics Ltd

29 Aug, 2025 | 11:20am • Source: NSE

ESG Rating by Crisil ESG Ratings & Analytics Ltd.

29 Aug, 2025 | 11:08am • Source: BSE

Intimation about participating in the Analyst/Investors Meet.

27 Aug, 2025 | 01:46pm • Source: BSE

Copies of Newspaper Publication with respect to dispatch of Postal Ballot Notice.

27 Aug, 2025 | 01:32pm • Source: BSE

Notice of Postal Ballot dated August 20, 2025, along with explanatory Statement.

26 Aug, 2025 | 03:36pm • Source: BSE

Intimation regarding allotment of 7189 shares under ESOP.

21 Aug, 2025 | 12:53pm • Source: BSE

Re-appointment of Mr. Mark D. McDade, Independent Director for Second term of five consecutive years.

20 Aug, 2025 | 06:20pm • Source: BSE